An interventional study of Black Mulberry Fruit Powder in Metabolic Syndrome, sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-11-03.
Sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 13th largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 6th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 18–45
Hamdard University · Sites in Pakistan
Ages 35–65
Asif Ali · Sites in Pakistan
Ages 30–60
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–55
University of Lahore · Sites in Pakistan
Ages 18–60
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 35 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 60 across the 16 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 9 most frequent:
University of Veterinary and Animal Sciences, Lahore - Pakistan is the lead sponsor of 29 studies on the registry; 15 are open to participants now.
University of Veterinary and Animal Sciences, Lahore - Pakistan has 5 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Metabolic syndrome is a raising concern globally, especially in developing countries such as Pakistan. To prevent its risk factors diet and lifestyle modification is major solution. Functional foods have additional benefits of treating disease while providing basic nutrients. Mulberry is a native fruit with the properties of functional food, it is rich in anthocyanin and different anti-obesity,anti-diabetic, and anti-hyperlipidemic treating potential antioxidants. Mulberry will prove its therapeutic potential against the risk factors of metabolic syndrome.
Metabolic syndrome, which is characterized by a number of concurrent risk factors. These risk factors include dysglycemia, high blood pressure, high triglyceride levels, low levels of HDL cholesterol, and obesity (particularly central adiposity). It is rapidly increasing the burden of non-communicable diseases (NCDs) in Pakistan. The prevalence of MetS in Pakistan is 28.6%, and suburban areas from the province of Punjab showed a high prevalence. Females are more prone to metabolic syndrome. Dietary and lifestyle modification can prevent MetS from converting into CVD, T2DM, and stroke. There is limited documented research in Pakistan related to the therapeutic roles of mulberry fruit powder. With respect to these limitations, the present study aims to assess the therapeutic roles of mulberry fruit powder consumption on metabolic syndrome.
The utilization of dried mulberry fruit powder (MFP) as a component of nutritional supplementation will effectively ameliorate the clinical markers associated with metabolic syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dried Mulberry fruit powder is used for preventing symptoms in Metabolic Syndrome patients Dietary intervention: Black Mulberry fruit powder Dosage: 45g per day
Dietary Supplement: Black Mulberry Fruit Powder
Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
Also known as: Morus Nigra
Lipid profile will be assessed before and after the trial.
The change in lipid profile, after consuming mulberry fruit powder for 45 days, will be assessed. The value will be closed to optimized values.
Time frame: 45 days
Fasting glucose level will be assessed before and after the trial
The change in fasting glucose levels will be assessed after consuming mulberry fruit powder for 45 days.The values will be become close to optimized levels
Time frame: 45 days
Weight circumference will be measured before and after the trial
The change in weight will be measured after consuming mulberry fruit powder for 45 days.The value will be close to normal range.
Time frame: 45 days
Blood pressure will be assessed before and after the trial.
The change in systolic and diastolic blood pressure, after consuming mulberry fruit powder for 45 days. The values will become close to optimized levels.
Time frame: 45 days
Plan to share: No — All available data will be confidential
Started Aug 2023 (actual). Primary completion is estimated for Dec 2023, 4 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 4 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Veterinary and Animal Sciences, Lahore - Pakistan